Upstate Active Clinical Trials
Study Title:
ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)Upstate Institutional Review Board (IRB) Number:
1601784Study/Protocol ID:
ANBL1531Study Phase:
IIIPatient Age Group:
ChildrenPrincipal Investigator:
Philip MonteleoneWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: bilynskk@upstate.edu